Optimization of the first small-molecule relaxin/insulin-like family peptide receptor (RXFP1) agonists: Activation results in an antifibrotic gene expression profile
Kenneth J. Wilson(National Institutes of Health), Juan Marugán(National Institutes of Health), Emmett R. George(National Institutes of Health), Wei Zheng(Liaoning Cancer Hospital & Institute), Noel Southall(National Institutes of Health), Irina U. Agoulnik(University of South Florida), Alexander I. Agoulnik(Florida International University), Elena Barnaeva(National Center for Advancing Translational Sciences), Xin Hu(Discovery Institute), Amy Wang(National Institutes of Health), Xin Xu(National Institutes of Health), Zaohua Huang(Florida International University), Jingbo Xiao(National Center for Advancing Translational Sciences), Marc Ferrer(National Institute of Biomedical Innovation, Health and Nutrition), Courtney Myhr(Florida International University), Catherine Z. Chen(National Institutes of Health)
Cited by 17
Related Papers
Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus
|Nature Medicine|2016|570
Rethinking dog domestication by integrating genetics, archeology, and biogeography
|Proceedings of the National Academy of Sciences|2012|534
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
|British Journal of Pharmacology|2023|390
A transgenic insertion upstream of Sox9 is associated with dominant XX sex reversal in the mouse
|Nature Genetics|2000|351